{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:42:05Z","timestamp":1790109725598,"version":"4.0.1"},"reference-count":53,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuromuscular disorders can cause respiratory impairment by affecting the muscle fibers, neuromuscular junction, or innervation of respiratory muscles, leading to significant morbidity and mortality. Over the past few years, new disease-modifying therapies have been developed and made available for treating different neuromuscular disorders. Some of these therapies have remarkable effectiveness, resulting in the prevention and reduction of respiratory complications. For myasthenia gravis (MG), efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan have been Food and Drug Administration (FDA)-approved for the treatment of acetylcholine receptor (AChR) antibody-positive generalized MG in the past 2 years. Rozanolixiumab is also approved for treating MG caused by muscle-specific tyrosine kinase (MuSK) antibodies. The new MG therapeutics target the complement system or block the neonatal fragment crystallizable (Fc) receptors (FcRn), leading to significant clinical improvement. For spinal muscular atrophy (SMA), nusinersen (intrathecal route) and risdiplam (oral route) modify the splicing of the SMN2 gene, increasing the production of normal survival motor neuron (SMN) protein. Onasemnogene abeparvovec is a gene replacement therapy that encodes a functional SMN protein. All SMA medications, particularly onasemnogene abeparvovec, have led to clinically meaningful improvement. For late-onset Pompe disease (LOPD), avalglucosidase alfa has shown a greater improvement in respiratory function, ambulation, and functional outcomes in comparison to alglucosidase alfa, and cipaglucosidase alfa combined with miglustat has shown improvement in respiratory and motor function in a cohort of enzyme replacement therapy-experienced LOPD patients. Amyotrophic lateral sclerosis (ALS) remains a challenge. The two most recent FDA-approved medications, namely sodium phenylbutyrate and tofersen, may slow down the disease by a few months in a selected population but do not stop the progression of the disease.<\/jats:p>","DOI":"10.1055\/a-2463-3385","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T18:56:01Z","timestamp":1734807361000},"page":"250-258","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders"],"prefix":"10.1055","volume":"46","author":[{"given":"Long","family":"Davalos","sequence":"additional","affiliation":[{"name":"Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3786-1133","authenticated-orcid":false,"given":"Hani","family":"Kushlaf","sequence":"additional","affiliation":[{"name":"Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: a clinical review","volume":"27","author":"P Masrori","year":"2020","journal-title":"Eur J Neurol"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature","volume":"41","author":"A Chi\u00f2","year":"2013","journal-title":"Neuroepidemiology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/17482960802566824","article-title":"Prognostic factors in ALS: a critical review","volume":"10","author":"A Chi\u00f2","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fnins.2019.01310","article-title":"ALS genetics, mechanisms, and therapeutics: where are we now?","volume":"13","author":"R Mejzini","year":"2019","journal-title":"Front Neurosci"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s40265-022-01769-1","article-title":"Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents","volume":"82","author":"S A Johnson","year":"2022","journal-title":"Drugs"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"105156","DOI":"10.1016\/j.nbd.2020.105156","article-title":"The genetic architecture of ALS","volume":"147","author":"A Shatunov","year":"2021","journal-title":"Neurobiol Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature20413","article-title":"Decoding ALS: from genes to mechanism","volume":"539","author":"J P Taylor","year":"2016","journal-title":"Nature"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3390\/cells12111523","article-title":"Current state and future directions in the therapy of ALS","volume":"12","author":"L Tzeplaeff","year":"2023","journal-title":"Cells"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"G Bensimon","year":"1994","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1212\/WNL.47.6_Suppl_4.242S","article-title":"A confirmatory dose-ranging study of riluzole in ALS","volume":"47","author":"L Lacomblez","year":"1996","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/21678421.2020.1771734","article-title":"Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis","volume":"21","author":"J A Andrews","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients","volume":"15","author":"K Abe","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Writing Group","year":"2017","journal-title":"Lancet Neurol"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"79","author":"S Witzel","year":"2022","journal-title":"JAMA Neurol"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1007\/s00415-020-09993-z","article-title":"The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis","volume":"267","author":"C Lunetta","year":"2020","journal-title":"J Neurol"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17482960802320487","article-title":"Phase 2 study of sodium phenylbutyrate in ALS","volume":"10","author":"M E Cudkowicz","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/ene.12664","article-title":"Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis","volume":"23","author":"A E Elia","year":"2016","journal-title":"Eur J Neurol"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis","volume":"383","author":"S Paganoni","year":"2020","journal-title":"N Engl J Med"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/jnnp-2022-329024","article-title":"Effect of sodium phenylbutyrate\/taurursodiol on tracheostomy\/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial","volume":"93","author":"S Paganoni","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.27091","article-title":"Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis","volume":"63","author":"S Paganoni","year":"2021","journal-title":"Muscle Nerve"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/17482960802226148","article-title":"Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice","volume":"10","author":"S J Del Signore","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03077.x","article-title":"Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice","volume":"93","author":"H Ryu","year":"2005","journal-title":"J Neurochem"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3390\/cells8121471","article-title":"Tauroursodeoxycholate-bile acid with chaperoning activity: molecular and cellular effects and therapeutic perspectives","volume":"8","author":"M Kusaczuk","year":"2019","journal-title":"Cells"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neurobiolaging.2014.08.034","article-title":"Amyloid-\u03b2 pathology is attenuated by tauroursodeoxycholic acid treatment in APP\/PS1 mice after disease onset","volume":"36","author":"P A Dion\u00edsio","year":"2015","journal-title":"Neurobiol Aging"},{"issue":"07","key":"ref25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jnnp-2016-315018","article-title":"Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"88","author":"Z Y Zou","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"T M Miller","year":"2022","journal-title":"N Engl J Med"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/mus.26899","article-title":"Intrathecal delivery of nusinersen in individuals with complicated spines","volume":"62","author":"M S Cartwright","year":"2020","journal-title":"Muscle Nerve"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CND.0000000000000333","article-title":"Delivery of nusinersen through an ommaya reservoir in spinal muscular atrophy","volume":"22","author":"S T Iannaccone","year":"2021","journal-title":"J Clin Neuromuscul Dis"},{"issue":"18","key":"ref29","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"R S Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"07","key":"ref30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"E Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"G Baranello","year":"2021","journal-title":"N Engl J Med"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"E Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"J W Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"E Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"K A Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"26","key":"ref36","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"N E Gilhus","year":"2016","journal-title":"N Engl J Med"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"B Neumann","year":"2020","journal-title":"Neurology"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"J McConville","year":"2004","journal-title":"Ann Neurol"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/mus.20854","article-title":"Frequency of seronegativity in adult-acquired generalized myasthenia gravis","volume":"36","author":"K H Chan","year":"2007","journal-title":"Muscle Nerve"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/mus.26695","article-title":"Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment","volume":"60","author":"G Cutter","year":"2019","journal-title":"Muscle Nerve"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"J F Howard Jr","year":"2017","journal-title":"Lancet Neurol"},{"issue":"05","key":"ref42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"M K Hehir","year":"2010","journal-title":"Muscle Nerve"},{"issue":"07","key":"ref43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"J F Howard Jr","year":"2021","journal-title":"Lancet Neurol"},{"issue":"05","key":"ref45","first-page":"a2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"T Vu","year":"2022","journal-title":"NEJM Evid"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"V Bril","year":"2023","journal-title":"Lancet Neurol"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"J F Howard Jr","year":"2023","journal-title":"Lancet Neurol"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/mus.21393","article-title":"Diagnostic criteria for late-onset (childhood and adult) Pompe disease","volume":"40","author":"American Association of Neuromuscular & Electrodiagnostic Medicine","year":"2009","journal-title":"Muscle Nerve"},{"issue":"23","key":"ref49","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"E Kuperus","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/bc400365a","article-title":"Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein","volume":"24","author":"Q Zhou","year":"2013","journal-title":"Bioconjug Chem"},{"issue":"12","key":"ref51","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"J Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1750-1172-8-160","article-title":"The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?","volume":"8","author":"R Lachmann","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","article-title":"Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial","volume":"80","author":"P S Kishnani","year":"2023","journal-title":"JAMA Neurol"},{"issue":"12","key":"ref54","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"B Schoser","year":"2021","journal-title":"Lancet Neurol"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2463-3385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:39:54Z","timestamp":1757457594000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2463-3385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":53,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,9,9]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2463-3385","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]}}}